
Please try another search
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. Its lead products include SNK01, an autologous NK cell therapy candidate for the treatment of neurodegenerative diseases, and SNK02, an allogeneic NK cell therapy for refractory solid tumors. The company has a license agreement with NKMAX for its NK cell program. The company has a strategic partnership with HekaBio K.K. for the development of the company's autologous NK cell therapy, troculeucel, in Japan. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Name | Age | Since | Title |
---|---|---|---|
Paul Y. Song | 58 | 2023 | CEO & Chairman |
Ming Guo | - | 2023 | Member of Scientific Advisory Board |
Michael L. Klowden | 78 | 2023 | Independent Director |
Craig Blackstone | - | 2023 | Member of Scientific Advisory Board |
Kathleen D. Scott | - | 2023 | Independent Director |
Anthony T. Reder | - | 2023 | Member of Scientific Advisory Board |
Marco Gottardis | 67 | 2024 | Independent Director |
Evren Alici | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review